动态影像揭示肺结核患者肺部病灶药物暴露的异质性
本研究在利福平敏感肺结核患者中首次开展动态[11C]利福平PET-CT检查,发现同一患者不同病理类型结核病灶内利福平暴露存在空间分区差异,空洞壁暴露低。重复PET-CT显示不同病灶药物暴露轨迹随时间独立演变,兔模型和死后质谱验证类似发现。基于中空纤维杀菌曲线实验的建模估算了4个月治愈所需利福平剂量。
要点
- 同一患者不同结核病灶内利福平暴露存在空间异质性,空洞壁暴露低。
- 重复PET-CT显示不同病灶药物暴露轨迹随时间独立演变。
- 基于PET浓度-时间曲线建模可估算缩短疗程所需利福平剂量。
核心结论
- 肺结核患者肺部病灶内利福平暴露存在空间和时间异质性,对优化抗菌药物剂量和缩短疗程有重要意义。
研究设计与样本
- 首次人体研究,纳入新诊断的利福平敏感肺结核患者,采用动态[11C]利福平微剂量PET-CT进行无创多腔室浓度-时间测量。
- 另在实验感染空洞性结核的兔中行PET-CT,并用死后质谱确认。
主要发现
- PET-CT安全,显示同一患者病理 distinct 结核病灶内利福平暴露呈空间分区,空洞壁利福平暴露低。
- 重复PET-CT显示同一患者不同病灶利福平暴露轨迹随时间独立演变。
- 兔实验感染空洞性TB的PET-CT重现类似发现,死后质谱确认。
- 中空纤维杀菌曲线实验整合建模估算4个月治愈所需利福平剂量。
临床怎么用
- 提示临床应关注病灶内药物暴露异质性,尤其空洞壁低暴露可能影响疗效。
- 为抗菌药物开发和剂量优化提供病灶水平药代动力学依据。
局限性
- 首次人体研究,样本量小,结论需进一步验证。
- 使用微剂量[11C]利福平,与治疗剂量下的暴露可能不完全一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tuberculosis (TB) is the leading cause of death from a single infectious agent, requiring at least 6 months of multidrug treatment to achieve cure1. However, the lack of reliable data on antimicrobial pharmacokinetics (PK) at infection sites hinders efforts to optimize antimicrobial dosing and shorten TB treatments2. In this study, we applied a new tool to perform unbiased, noninvasive and multicompartment measurements of antimicrobial concentration-time profiles in humans3. Newly identified patients with rifampin-susceptible pulmonary TB were enrolled in a first-in-human study4 using dynamic [11C]rifampin (administered as a microdose) positron emission tomography (PET) and computed tomography (CT). [11C]rifampin PET-CT was safe and demonstrated spatially compartmentalized rifampin exposures in pathologically distinct TB lesions within the same patients, with low cavity wall rifampin exposures. Repeat PET-CT measurements demonstrated independent temporal evolution of rifampin exposure trajectories in different lesions within the same patients. Similar findings were recapitulated by PET-CT in experimentally infected rabbits with cavitary TB and confirmed using postmortem mass spectrometry. Integrated modeling of the PET-captured concentration-time profiles in hollow-fiber bacterial kill curve experiments provided estimates on the rifampin dosing required to achieve cure in 4 months. These data, capturing the spatial and temporal heterogeneity of intralesional drug PK, have major implications for antimicrobial drug development.
引用
- Ordonez AA, Wang H, Magombedze G, et al. Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions. Nat Med. 2020. PMID: 32066976. doi:10.1038/s41591-020-0770-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。